Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Social Networks
  9. External Links
  10. Libraries
  11. Hosting Providers

We began analyzing https://www.medsci.org/v19p0286.htm, but it redirected us to https://www.medsci.org/v19p0286.htm. The analysis below is for the second page.

Title[redir]:
Gemcitabine and XCT790, an ERRΞ± inverse agonist, display a synergistic anticancer effect in pancreatic cancer
Description:
No description found...

Matching Content Categories {πŸ“š}

  • Science
  • Health & Fitness
  • Education

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

πŸ™οΈ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 91,115,781 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {πŸ”}

gemcitabine, xct, cell, cells, errΞ±, cancer, treatment, combination, effect, pancreatic, figure, synergistic, group, cycle, analysis, cellular, andor, results, resistance, minipdx, mekerk, synergism, activity, anticancer, emt, pathway, inhibition, mice, shanghai, tumor, assay, apoptosis, liu, study, apoptotic, growth, hours, data, medicine, drug, synergistically, inverse, agonist, yang, zheng, viability, assays, xenograft, models, therapy,

Topics {βœ’οΈ}

gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine estrogen-related receptor alpha mini patient-derived xenografts mini-pdx capsules-bearing mice g0/g1 retardation cdc25c/cdk1/cyclinb1 pathway erk/mapk signalling pathway mek/erk signal path micro-plate reading device mek/erk signaling pathway steponeplus real-time thermocycle vivo drug-response assay g0/g1 phase mek/erk pathway proteins mek/erk pathway plays patient-derived xenograft cellular cycle arrest cell cycle arrest uplifted long-period results cellular cycle assay programmed cell death cellular cycle-related sera-reduced dmem medium cellular cycle analysis cellular cycle arrested cell cycle distribution cell viability assays estrogen-related receptors pancreatic ductal adenocarcinoma apoptotic activity-related markers flow cell technique cell signaling technology mek/erk pathway western blot analysis mini-pdx assay xct790 dramatically inhibited international journal cell commun signal authors contributed equally castration-resistant growth xct790 synergistically suppress annu rev physiol xct790 synergistically decreased nat rev cancer gemcitabine-based chemical therapy xct790 potently inhibited remarkably reduced compared entire lineage cells guided chemotherapy based febs open bio

External Links {πŸ”—}(84)

Libraries {πŸ“š}

  • Prism.js
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com
2.48s.